Peptides · Growth Hormone Axis

Tesamorelin

Egrifta · TH9507

FDA-approved (US) · not registered in Australia

A stabilised analogue of growth-hormone-releasing hormone (GHRH) and one of the few compounds on this list that is a genuinely approved medicine — the FDA approved it to reduce excess abdominal fat in people with HIV-associated lipodystrophy.

At a glance

  • FDA-approved for HIV-associated lipodystrophy since 2010
  • Reduced visceral fat ~15–18% in phase 3 trials
  • Being studied in liver fat and cognitive research
  • No ARTG registration — not available as a medicine in Australia

How it works

Tesamorelin stimulates the pituitary to release the body's own growth hormone in a more physiological pattern than injected HGH, raising IGF-1 and preferentially reducing visceral (deep abdominal) fat.

What the research shows

Phase 3 trials in HIV-associated lipodystrophy showed roughly 15–18% reductions in visceral fat over 6–12 months. Research interest continues in other conditions, including NAFLD and cognition, but its approval remains narrow.

Regulatory status

Australia

Not registered on the ARTG — there is no approved tesamorelin product in Australia. Any access would require special-access pathways through a prescriber.

Worldwide

FDA-approved since 2010 for HIV-associated lipodystrophy (marketed as Egrifta). Not broadly approved for fat loss in the general population. WADA prohibits GHRH analogues in sport.

Latest Tesamorelin articles

14 September 2026

Tesamorelin Dosing: Why 1.28 mg Now Equals 2 mg

Tesamorelin's approved dose fell from 2 mg to 1.28 mg with no change to the molecule. The sub-4% bioavailability story, the bioequivalence data, and the Australian status.

This is general information, not medical advice. retatrutide.net.au is an independent publication. Unless stated otherwise above, this compound is not an approved medicine in Australia, and this page does not endorse or facilitate its use. Speak to a registered health practitioner about any treatment decision.

Stay informed

Be first to know.
When it reaches Australia.

Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:

  • The latest clinical trial results and news from Eli Lilly
  • Updates on TGA regulatory progress in Australia
  • How and where to access Retatrutide when it becomes available
  • Occasional information from retatrutide.net.au and our affiliated partners
TGA review expected 2027 — subscribers hear the moment the status changes.

Get the free guide + updates

Enter your details once on our free access guide page — instant download, plus we'll email you the moment there's real news.

Sign up now
Tesamorelin — Research, Evidence & Australian Status | Retatrutide Australia